PMID- 19572414
OWN - NLM
STAT- MEDLINE
DCOM- 20100308
LR  - 20191111
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 72
IP  - 3
DP  - 2009 Aug
TI  - The enhancement of interstitial transport of a doxorubicin-lactosaminated albumin 
      conjugate by imatinib: in rat hepatocellular carcinoma it is not preferentially 
      higher than that in liver and bone marrow.
PG  - 630-1
AB  - The finding that imatinib enhances the drug transport from bloodstream to 
      neoplastic cells suggested a possible role of this drug as an adjuvant to the 
      chemotherapeutics given in the treatment of solid malignancies.The present 
      experiments aimed to verify whether imatinib can selectively increase the 
      penetration of a doxorubicin-lactosaminated human albumin conjugate (L-HSA-DOXO) 
      in chemically induced rat hepatocellular carcinomas (HCCs). We observed that 
      imatinib increased the uptake of L-HSA-DOXOby HCCs but at the same time caused a 
      similar enhanced penetration of the conjugate in liver and bone marrow. To our 
      knowledge, this is the first demonstration that the enhancing effect of imatinib 
      on interstitial drug transport is not restricted to the tumors, but can be also 
      displayed in normal tissues. This observation casts some doubts about the 
      possibility that the value of anticancer agents with toxic side effects on liver 
      and bone marrow can be improved by imatinib.
FAU - Fiume, L
AU  - Fiume L
AD  - Department of Experimental Pathology, University of Bologna, Italy. 
      luigi.fiume@unibo.it
FAU - Baglioni, M
AU  - Baglioni M
FAU - Busi, C
AU  - Busi C
FAU - Manerba, M
AU  - Manerba M
FAU - Di Stefano, G
AU  - Di Stefano G
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Benzamides)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Serum Albumin)
RN  - 0 (lactosaminated serum albumin)
RN  - 80168379AG (Doxorubicin)
RN  - 8A1O1M485B (Imatinib Mesylate)
SB  - IM
MH  - Animals
MH  - Benzamides
MH  - Biological Transport/drug effects/physiology
MH  - Bone Marrow/drug effects/metabolism
MH  - Carcinoma, Hepatocellular/*metabolism
MH  - Doxorubicin/chemistry/*pharmacokinetics
MH  - Drug Synergism
MH  - Extracellular Fluid/drug effects/*metabolism
MH  - Humans
MH  - Imatinib Mesylate
MH  - Liver/drug effects/metabolism
MH  - Liver Neoplasms, Experimental/*metabolism
MH  - Male
MH  - Piperazines/chemistry/*pharmacokinetics
MH  - Pyrimidines/chemistry/*pharmacokinetics
MH  - Rats
MH  - Rats, Wistar
MH  - Serum Albumin/chemistry/*pharmacokinetics
EDAT- 2009/07/03 09:00
MHDA- 2010/03/10 06:00
CRDT- 2009/07/03 09:00
PHST- 2009/07/03 09:00 [entrez]
PHST- 2009/07/03 09:00 [pubmed]
PHST- 2010/03/10 06:00 [medline]
AID - S0939-6411(09)00058-7 [pii]
AID - 10.1016/j.ejpb.2009.02.004 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2009 Aug;72(3):630-1. doi: 10.1016/j.ejpb.2009.02.004.